Actively Recruiting
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Led by Guangzhou Virotech Pharmaceutical Co., Ltd. · Updated on 2025-12-30
30
Participants Needed
3
Research Sites
127 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.
CONDITIONS
Official Title
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to participate and able to sign informed consent
- Males and females aged 18 to 75 years
- Diagnosed with locally advanced or metastatic solid tumors not responding to standard therapy
- Have at least one lesion that can be injected
- ECOG performance status of 0 or 1
- Estimated survival of at least 12 weeks
You will not qualify if you...
- Received any anti-tumor treatment within 4 weeks before study drug
- Previously treated with oncolytic viruses or gene therapies
- History of immunodeficiency, leukemia, lymphoma, AIDS, or related infections
- On immunosuppressive therapy
- Used immunomodulatory drugs like thymosin, IL-2, or interferon within 14 days before treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
2
Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
3
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Actively Recruiting
Research Team
H
Hongyun Zhao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here